Table 4.
The correlations among variables (N = 134).
| MMSE | Disease duration | H&Y stage | UPDRS | UPDRS part I | UPDRS part II | UPDRS part III | UPDRS part VI | BAI | BDI | PDSS-2 | LEDD | PDQ-39 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| MMSE | — | ||||||||||||
| Disease duration | −0.02 | — | |||||||||||
| H&Y stage | −0.15 | 0.34∗∗ | — | ||||||||||
| UPDRS | −0.17 | 0.53∗∗ | 0.59∗∗ | — | |||||||||
| UPDRS part I | −0.15 | 0.29∗∗ | 0.35∗∗ | 0.39∗∗ | — | ||||||||
| UPDRS part II | −0.13 | 0.52∗∗ | 0.55∗∗ | 0.88∗∗ | 0.41∗∗ | — | |||||||
| UPDRS part III | −0.22∗∗ | 0.32∗∗ | 0.51∗∗ | 0.87∗∗ | 0.33∗∗ | 0.68∗∗ | — | ||||||
| UPDRS part VI | 0.23∗∗ | 0.46∗∗ | 0.18∗ | 0.48∗∗ | 0.23∗∗ | 0.45∗∗ | 0.17 | — | |||||
| BAI | −0.03 | 0.26∗∗ | 0.20∗ | 0.40∗∗ | 0.35∗∗ | 0.44∗∗ | 0.20∗ | 0.47∗∗ | — | ||||
| BDI | −0.13 | 0.30∗∗ | 0.21∗ | 0.34∗∗ | 0.44∗∗ | 0.36∗∗ | 0.15 | 0.35∗∗ | 0.58∗∗ | — | |||
| PDSS-2 | 0.05 | 0.32∗∗ | 0.39∗∗ | 0.44∗∗ | 0.16 | 0.47∗∗ | 0.27∗∗ | 0.39∗∗ | 0.43∗∗ | 0.39∗∗ | — | ||
| LEDD | 0.01 | 0.56∗∗ | 0.42∗∗ | 0.56∗∗ | 0.29∗∗ | 0.59∗∗ | 0.34∗∗ | 0.48∗∗ | 0.28∗∗ | 0.27∗∗ | 0.40∗∗ | — | |
| PDQ-39 | −0.24∗∗ | 0.35∗∗ | 0.31∗∗ | 0.58∗∗ | 0.46∗∗ | 0.62∗∗ | 0.38∗∗ | 0.42∗∗ | 0.65∗∗ | 0.68∗∗ | 0.38∗∗ | 0.35∗∗ | — |
H&Y: Hoehn and Yahr scale; UPDRS: Unified Parkinson's Disease Rating Scale; BAI: Beck Anxiety Inventory; BDI: Beck Depression Inventory; PDSS-2: Parkinson's Disease Sleep Scale-2; PDQ-39: 39-item Parkinson's Disease Questionnaire; LEDD: levodopa equivalent daily dosage. ∗ p < 0.05 and ∗∗ p < 0.01.